353 related articles for article (PubMed ID: 23394580)
1. MiR-200c and HuR in ovarian cancer.
Prislei S; Martinelli E; Mariani M; Raspaglio G; Sieber S; Ferrandina G; Shahabi S; Scambia G; Ferlini C
BMC Cancer; 2013 Feb; 13():72. PubMed ID: 23394580
[TBL] [Abstract][Full Text] [Related]
2. HuR regulates beta-tubulin isotype expression in ovarian cancer.
Raspaglio G; De Maria I; Filippetti F; Martinelli E; Zannoni GF; Prislei S; Ferrandina G; Shahabi S; Scambia G; Ferlini C
Cancer Res; 2010 Jul; 70(14):5891-900. PubMed ID: 20587520
[TBL] [Abstract][Full Text] [Related]
3. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
4. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.
Cittelly DM; Dimitrova I; Howe EN; Cochrane DR; Jean A; Spoelstra NS; Post MD; Lu X; Broaddus RR; Spillman MA; Richer JK
Mol Cancer Ther; 2012 Dec; 11(12):2556-65. PubMed ID: 23074172
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
[TBL] [Abstract][Full Text] [Related]
7. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
8. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
9. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
10. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
Vescarelli E; Gerini G; Megiorni F; Anastasiadou E; Pontecorvi P; Solito L; De Vitis C; Camero S; Marchetti C; Mancini R; Benedetti Panici P; Dominici C; Romano F; Angeloni A; Marchese C; Ceccarelli S
J Exp Clin Cancer Res; 2020 Jan; 39(1):3. PubMed ID: 31898520
[TBL] [Abstract][Full Text] [Related]
11. miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.
Balkhi MY; Iwenofu OH; Bakkar N; Ladner KJ; Chandler DS; Houghton PJ; London CA; Kraybill W; Perrotti D; Croce CM; Keller C; Guttridge DC
Sci Signal; 2013 Jul; 6(286):ra63. PubMed ID: 23901138
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.
Denkert C; Weichert W; Pest S; Koch I; Licht D; Köbel M; Reles A; Sehouli J; Dietel M; Hauptmann S
Cancer Res; 2004 Jan; 64(1):189-95. PubMed ID: 14729623
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological significance of HuR expression in gallbladder carcinoma: with special emphasis on the implications of its nuclear and cytoplasmic expression.
Sun DP; Lin CY; Tian YF; Chen LT; Lin LC; Lee SW; Hsing CH; Lee HH; Shiue YL; Huang HY; Li CF; Liang PI
Tumour Biol; 2013 Oct; 34(5):3059-69. PubMed ID: 23722602
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic Role of miR-200c-3p in High-Grade Serous Ovarian Cancer Progression via Targeting the 3'-Untranslated Region of DLC1.
Ankasha SJ; Shafiee MN; Abdul Wahab N; Raja Ali RA; Mokhtar NM
Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34071861
[TBL] [Abstract][Full Text] [Related]
15. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C.
Chang TH; Tsai MF; Gow CH; Wu SG; Liu YN; Chang YL; Yu SL; Tsai HC; Lin SW; Chen YW; Kuo PY; Yang PC; Shih JY
Cancer Lett; 2017 Aug; 402():190-202. PubMed ID: 28610956
[TBL] [Abstract][Full Text] [Related]
17. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.
Fu X; Li Y; Alvero A; Li J; Wu Q; Xiao Q; Peng Y; Hu Y; Li X; Yan W; Guo K; Zhou W; Wang Y; Liu J; Zhang Y; Mor G; Wen J; Yin G
Oncotarget; 2016 Dec; 7(49):80633-80654. PubMed ID: 27811362
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer.
Cao Q; Lu K; Dai S; Hu Y; Fan W
Int J Clin Exp Pathol; 2014; 7(5):2392-401. PubMed ID: 24966949
[TBL] [Abstract][Full Text] [Related]
20. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
